Hydrogen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Hydrogen

Accession Number

DB15127

Description

Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).

Type

Small Molecule

Groups

Investigational

Synonyms

: Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication: Not Available
Contraindications & Blackbox Warnings: Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

General References

Not Available

External Links

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Recruiting	Treatment	Coronary Artery Disease (CAD) / Percutaneous Coronary Intervention (PCI)	1
3	Completed	Treatment	Onychomycosis	1
3	Recruiting	Treatment	Astrocytomas / Low Grade Glioma (LGG)	1
3	Recruiting	Treatment	Low Grade Glioma (LGG) / Neurofibromatosis Type 1 / Visual Pathway Glioma	1
3	Recruiting	Treatment	Recurrent Low Grade Astrocytoma / Recurrent WHO Grade II Glioma	1
3	Unknown Status	Treatment	Evidence of Liver Transplantation	1
2	Active Not Recruiting	Treatment	Advanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Refractory Primary Central Nervous System Neoplasm	1
2	Completed	Treatment	Borderline Ovarian Serous Tumor / Low Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Primary Peritoneal Carcinoma / Primary Peritoneal Low Grade Serous Adenocarcinoma / Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor	1
2	Completed	Treatment	KRAS NP_004976.2:p.G12R / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer AJCC v6 and v7	1
2	Not Yet Recruiting	Treatment	Cutaneous Neurofibromas / Neurofibromatosis Type 1	1

Drug created on May 20, 2019 14:52 / Updated on June 12, 2020 16:53